Loading...
Market
What will be the total revenue generated by Zenrelia™ in its first year post-approval?
2
Resolution / Starting Odds
Less than $100 million • 25%
$100 million to $200 million • 25%
$200 million to $300 million • 25%
More than $300 million • 25%
Elanco's annual financial reports
Story
FDA Approves Elanco's Zenrelia™ for Dogs, Shares Up 2%
Sep 19, 2024, 07:18 PM
The U.S. Food and Drug Administration (FDA) has approved Elanco Animal Health's new skin disease treatment for dogs, Zenrelia™ (ilunocitinib tablets). This approval marks a significant advancement in canine dermatology, offering an effective and safe solution for treating skin conditions in dogs. The announcement has positively impacted Elanco's market performance, with the company's shares rising by 2% in afternoon trade.
View original story
Similar markets
Less than $100 million • 25%
$100 million to $299 million • 25%
$300 million to $499 million • 25%
$500 million or more • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $200 million • 25%
More than $200 million • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $100M • 25%
$100M - $500M • 25%
$500M - $1B • 25%
More than $1B • 25%
Less than $50 million • 25%
$50 million - $100 million • 25%
$100 million - $150 million • 25%
More than $150 million • 25%
Less than $20 million • 25%
$20 million to $25 million • 25%
$25 million to $30 million • 25%
More than $30 million • 25%